Cenexel Acquires Apex Innovative Sciences

CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman Research Institute (HRI), which will be renamed as “CenExel CNS” and “CenExel HRI”, respectively, going forward. CenExel CNS and CenExel HRI consist of five prominent clinical research sites across California and New Jersey with significant expertise in early phase complex clinical trials and particular emphasis on central nervous system (CNS) indications. CenExel CNS will continue to be led by Dr. David Walling, while CenExel HRI will continue under the direction of Dr. Howard Hassman. Both leaders have decades of experience conducting Phase I-IV studies across a variety of CNS medical specialties. The primary therapeutic areas served by these five Centers include Complex Early Phase normal healthy volunteer (NHV) and patient studies, Psychiatry, Addiction (including human abuse liability/human abuse potential), Neurology, Pain, Ethnic Bridging, and General Medicine (particularly vaccine, endocrine, and infectious diseases).